Abstract 250P
Background
Seminoma is the most common type of germ cell tumors representing 95% of all testicular neoplasm with mean age at diagnosis of 39 years. The standard treatment modality for stage I/II is orchidectomy with high cure rate.There is an active debate regarding the use of adjuvant therapy in stage I/II due to the high relapse rate and potential for overtreatment with serious systemic side effects. The aim of this study is to assess the impact of adjuvant treatment in stage I and stage II seminoma comparing the young and adolescents to older age groups.
Methods
Data of 11718 patients diagnosed with seminoma stage I/II were obtained from the Surveillance, Epidemiology, and End Results (SEER) program from 2000 to 2020. They were grouped by age at diagnosis into younger than 25 years (young age group), 25 to 49 years ( middle age group) and older than 50 years (old age group). SPSS 23 was used for data analysis, Kaplan-Meier curve and log rank test for survival analysis.
Results
Patients treated surgically with no systemic therapy had 5-year relative survival of 99,4% compared to adjuvant chemotherapy (98.3%) and adjuvant radiotherapy(100%), P<0.0001. The middle age group had quite similar 5-year relative survival compared to the young age group and the elderly (99.5%, 99.3% and 99%; P<0.0001). In the young age group the 5-year relative survival was 99.9% with orchidectomy, 97.4% with adjuvant chemotherapy and 100% with adjuvant radiotherapy (p <0.0001). In the middle age group, the 5-year relative survival was 99.2% with surgery with no systemic therapy, 98.4% with adjuvant chemotherapy and 99,9% with adjuvant radiotherapy (p <0.0001) while the old age group had 5-year relative survival of 98.9% for orchidectomy, 97.5% with adjuvant chemotherapy and 99.6% with adjuvant radiotherapy(p <0.0001).
Conclusions
The use of adjuvant chemotherapy and radiotherapy for clinical stage I and stage II testicular seminoma came statistically significant. However, adjuvant systemic therapy has very limited survival benefit compared to surgical management with no systemic therapy which discourage the use of adjuvant therapy for less systemic side effects with similar overall survival across different age groups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract